Summarized by Masters of Longevity from BioSpace - Funding.
Engineered bacteria were reported to break down tumour matrices and enable drug access.
Key Takeaways
- Engineered bacteria were tested in triple negative breast cancer models.
- A single dose was reported to produce complete tumour regression in one model.
- Preclinical work is ongoing and human efficacy remains unproven.
